Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026
The market has rewarded this biotech for its breakthroughs.
Healthcare stocks have rebounded in 2025, with Moderna (MRNA +1.55%) emerging as the standout performer in the large-cap sector. Moderna's stock has skyrocketed over 600% since the beginning of the year, driven by the approval of its new influenza vaccine, mFLUSIVA, for adults aged 50 and older. This approval is significant as it opens a multibillion-dollar market for the company.
However, Moderna's recent stock price surge has raised concerns among Wall Street analysts. Current market capitalization stands at $90 billion, with an average price target of $123.61, implying a potential downside of around 45% from its current level. Despite the promising outlook, factors such as the company's recent loss and the need for additional blockbuster products to meet analysts' expectations suggest that the stock may be overvalued at present.
Investors should cautiously consider Moderna's future prospects, keeping in mind the potential for significant clinical and regulatory wins in the upcoming years, but also acknowledging the challenges the company faces to maintain its impressive growth trajectory.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
